Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

Isunakinra clinical trials

Also listed in trial records as EBI-005
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA and Canada registers that name Isunakinra as an intervention. Synced 1 Nov 2026
2Current trials
2Recruiting now
2Lead sponsors
2Country registers
At a glance

Isunakinra is named as an intervention in 2 current clinical trials in our USA and Canada registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Buzzard Pharmaceuticals (1). The most-studied condition is Colorectal Cancer Metastatic.

Patient leaflets for Isunakinra

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting2100%

Trials by phase

  • Phase 2150%
  • Phase 1/2150%
01

Clinical trials of Isunakinra

2 trials
StudyPhaseStatusLead sponsorRegisters
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
NCT06634875 · Colorectal Cancer Metastatic
Phase 2 Recruiting Buzzard Pharmaceuticals USA
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
NCT07698106 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)
Phase 1/2 Recruiting University Health Network, Toronto Canada

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Isunakinra

2 conditions
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Buzzard Pharmaceuticals1
University Health Network, Toronto1
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA11
Clinical trials in Canada11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Isunakinra trials

How many clinical trials are testing Isunakinra?

2 current trials in our USA and Canada registers name Isunakinra (also registered as EBI-005) as a drug or biological intervention, as of the registry sync on 1 November 2026. Completed and withdrawn studies are not counted.

Are Isunakinra trials recruiting patients?

Yes. 2 of the 2 trials are recruiting: 1 with sites in USA and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Isunakinra clinical trials?

Buzzard Pharmaceuticals (1) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Isunakinra works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Isunakinra works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Isunakinra (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.